Vyome Holdings Inc HIND
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-10-06 |
| Shares Out. | 7,020,000 |
| Website | reshapelifesciences.com/obalon/ ↗ |
| Phone | 13026365400 |
| Employees | 18 |
| Revenue | $31,591 |
| Gross Profit | $16,645 |
| Net Income | -$985,521 |
| Total Assets | $10.2M |
| Total Liabilities | $2.1M |
| Equity | $8.0M |
About Vyome Holdings Inc
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
Vyome Holdings Inc is a publicly traded company under the ticker symbol HIND on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)